Blog
RSS FeedPosted by Michael Wonder on 22 May 2019
ICER releases draft evidence report on treatments for Duchenne muscular dystrophy
22 May 2019 - Public comment period now open until June 18, 2019; requests to make oral comment during public ...
Posted by Michael Wonder on 10 May 2019
Institute for Clinical and Economic Review's evidence report finds esketamine may benefit patients with treatment-resistant depression but exceeds cost-effectiveness thresholds
9 May 2019 - Midwest CEPAC to vote on overall value of esketamine during 23 May public meeting. ...
Posted by Michael Wonder on 03 May 2019
ICER publishes evidence report on the use of siponimod to treat secondary progressive multiple sclerosis
2 May 2019 - Midwest CEPAC to deliberate on the treatment’s clinical effectiveness and other potential benefits during its May ...
Posted by Michael Wonder on 03 Apr 2019
ICER issues final report on Spinraza and Zolgensma, provides policy recommendations related to pricing and coverage of treatments for spinal muscular atrophy
3 April 2019 - Independent appraisal committee notes family testimony in votes confirming broad benefits of both treatments; however, committee votes ...
Posted by Michael Wonder on 21 Mar 2019
Institute for Clinical and Economic Review releases draft evidence report on esketamine for treatment-resistant depression
21 March 2019 - Public comment period now open until 17 April 2019; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 14 Mar 2019
Institute for Clinical and Economic Review releases draft evidence report on siponimod for treating secondary progressive multiple sclerosis
14 March 2019 - Public comment period now open until 10 April 2019; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 22 Feb 2019
ICER’s assessment finds Spinraza and Zolgensma provide substantial health benefits for people with spinal muscular atrophy
22 February 2019 - Current pricing of Spinraza would require a substantial discount to meet traditional cost-effectiveness ranges; Zolgensma’s value-based price ...
Posted by Michael Wonder on 15 Feb 2019
ICER publishes final new evidence update for alirocumab, a PCSK9 inhibitor for treating high cholesterol
15 February 2019 - Based on new analyses of published results of the ODYSSEY Outcomes trial, alirocumab would meet cost-effectiveness thresholds ...
Posted by Michael Wonder on 20 Dec 2018
Institute for Clinical and Economic Review provides policy recommendations for biologic treatments for uncontrolled asthma
20 December 2018 - Expert roundtable suggests that lower prices, needed to align pricing fairly with the added value for patients, ...
Posted by Michael Wonder on 03 Dec 2018
Institute for Clinical and Economic Review provides policy recommendations for extended-release treatments for opioid use disorder
3 December 2018 - CAM2038 could reach fair value-based price if launched with annual price less than $5,300. ...
Posted by Michael Wonder on 16 Nov 2018
ICER issues final report on long-term prophylaxis for hereditary angioedema, provides policy recommendations to improve cost-effectiveness
15 November 2018 - Cost-effectiveness and coverage considerations hinge on the frequency and intensity of attacks. ...
Posted by Michael Wonder on 14 Nov 2018
ICER report finds biologic treatments for uncontrolled asthma would require more than a 50% price discount to reach common thresholds for cost-effectiveness
13 November 2018 - Midwest CEPAC to vote on the overall value of treatments during 29 November public meeting. ...
Posted by Michael Wonder on 26 Oct 2018
Institute for Clinical and Economic Review report finds extended-release treatments for opioid use disorder provide only marginal benefits over generic alternatives, at significantly higher prices
25 October 2018 - ICER report includes value-based annual price ranges for Probuphine, Vivitrol, and CAM2038. ...
Posted by Michael Wonder on 24 Oct 2018
Institute for Clinical and Economic Review ends assessment of canakinumab for atherosclerosis
24 October 2018 - The Institute for Clinical and Economic Review today announced that it will not proceed with its comparative ...
Posted by Michael Wonder on 11 Oct 2018
ICER finds treatments prevent hereditary angioedema attacks, but cost-effectiveness uncertain and sensitive to frequency of attacks
11 October 2018 - As with all treatments for ultra-rare conditions, judgments of overall value require consideration of the broader patient ...